Lilly and Boehringer report obesity drug wins at AHA meeting

· Health · United States

Eli Lilly and Boehringer Ingelheim reported positive late-stage results at the American Heart Association meeting, Endpoints News and STAT reported. Lilly's GLP-1 pill Foundayo helped alleviate obstructive sleep apnea in two late-stage studies, though it appeared less effective than Lilly's injectable Zepbound, and Lilly plans to seek approval in sleep apnea. Boehringer said it will seek approval next year for its incretin shot survodutide for obesity after a trial showed no increased risk of cardiovascular events. Both moves intensify competition in obesity and related conditions, where Novo's Wegovy currently leads.

Why it matters：Oral and next-generation obesity drugs are moving toward broader labels, intensifying competition in the fast-growing metabolic disease market.

Key points

  • Lilly plans to seek approval of Foundayo for sleep apnea.
  • Boehringer will seek survodutide approval for obesity next year.

Sources (original reporting)

More stories from this day